Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3347415 | Diagnostic Microbiology and Infectious Disease | 2011 | 4 Pages |
Abstract
Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and methicillin resistant Staphylococcus aureus (MRSA) are important nosocomial pathogens. This study reports the in vitro activity of tigecycline against 573 and 482 ESBL-producing Enterobacteriaceae and MRSA isolates, respectively. More than 94% of all tested isolates were susceptible to tigecycline; MIC90 found was 0.25 to 2 mg/L for ESBL-producing Enterobacteriaceae and was 0.125 mg/L for MRSA. Tigecycline demonstrated excellent in vitro activity against a wide spectrum of nosocomial pathogens.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Jesus Silva-Sanchez, Fernando Reyna-Flores, Ma. Elena Velazquez-Meza, Teresa Rojas-Moreno, Arturo Benitez-Diaz, Alejandro Sanchez-Perez,